Press releases

Cancel
  • © Photo Fraunhofer IZI

    Whether in medical engineering, biotechnology or microelectronics, new approaches are needed in the trend towards miniaturization in order to fabricate even smaller, more sensitive and more precise forms and structures. Together with colleagues from the Leibniz Institute of Surface Modification, researchers at the Fraunhofer Institute for Cell Therapy and Immunology have managed to lower this limit even further. Using a new printing method, the scientists demonstrated that surface modifications with a resolution of less than 10nm are now also possible.

    more info
  • The Main Department GMP Cell and Gene Therapy of Fraunhoferis collaborating with Iovance Biotherapeutics Inc. (San Carlos, CA, USA) on the technology transfer and subsequent continuous manufacturing of allogeneic feeder cells used in Iovances’ Tumor Infiltrating Lymphocyte manufacturing process. This collaboration supports Iovances’s upcoming European clinical trials for the treatment of solid tumors in metastatic melanoma and cervical carcinoma.

    more info
  • Detailaufnahme: Probenkammer des Lichtblattmikroskops
    © Photo Fraunhofer IZI

    On 12 August 2014, the Fraunhofer Institute for Cell Therapy and Immunology and Leipzig University of Applied Sciences (HTWK Leipzig) got the ball rolling on a joint specialist group focused on the “Image Analysis of Cell Function”. The group was evaluated and its future viability assessed on 4 August 2017, following a three-year start-up phase. The evaluation committee, made up of representatives from science, business and politics, attested to the outstanding work completed by the team, which is headed up by Professor Ulf-Dietrich Braumann, during this early phase and unanimously recommended that the specialist group be continued. The group's high level of commitment to the teaching and training of young scientists also received a special mention.

    more info
  • Antibodies against Alzheimer’s disease: researchers from Martin Luther University of Halle-Wittenberg (MLU), the Fraunhofer Institute for Cell Therapy and Immunology IZI and Halle-based company Probiodrug AG have succeeded in developing antibodies as potential active agents against the disease. At the same time, they have been able to describe the structure of a harmful form of the peptide associated with Alzheimer’s in detail for the first time. The research units are presenting their findings in the globally renowned “Journal of Biological Chemistry”.

    more info
  • © Photo Sean McDonald / Monash University

    The Fraunhofer IZI in Leipzig and the Bioanalytics and Bioprocesses branch (IZI-BB) in Potsdam, Germany, have got the ball rolling on a new research unit at Monash University in Melbourne, Australia. The collaboration is aimed at the joint development of innovative technologies and products in the fields of immunology and imaging.

    more info
  • © Photo MPI CBS

    Five years of common research has made it possible: An early test which recognises widespread dyslexia in time–and would therefore spare about five per cent of children a long path of suffering. Scientists at the Max Planck Institute for Human Cognitive and Brain Sciences and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) have succeeded in laying the foundations for a test which, with the help of brain activity and gene analyses, could predict whether a child could be affected by this disorder. The conclusion of their research project LEGASCREEN offers an opportunity to reflect on current and future dyslexia diagnosis.

    more info